Canada Life’s Juno Therapeutics, Inc. JUNO Stock Holding History

Canada Life’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,841	Closed	-$494K	–	2739
2017 Q4	$494K	Buy	10,841 +2,323	+27%	+$116K	﹤0.01%	1736
2017 Q3	$378K	Hold	8,518	–	–	﹤0.01%	1789
2017 Q2	$254K	Hold	8,518	–	–	﹤0.01%	1865
2017 Q1	$189K	Buy	8,518 +3,800	+81%	+$81.5K	﹤0.01%	1931
2016 Q4	$89K	Hold	4,718	–	–	﹤0.01%	2160
2016 Q3	$141K	Hold	4,718	–	–	﹤0.01%	2008
2016 Q2	$181K	Hold	4,718	–	–	﹤0.01%	1910
2016 Q1	$179K	Hold	4,718	–	–	﹤0.01%	1383
2015 Q4	$207K	Buy	+4,718	New	+$234K	﹤0.01%	1264

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Canada Life's JUNO Position: Q1 2018 in Review

Canada Life sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 10,841 shares — an estimated $494K sold.

Canada Life first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $494K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Canada Life reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Canada Life sold 10,841 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $494K.
Canada Life first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
Canada Life's Juno Therapeutics, Inc. position peaked at $494K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Canada Life's 13F filing for Q1 2018, filed 10 May 2018.